MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$1,905,689
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from the issuance of co...
Prepaid expenses and other curre...
Depreciation and amortization
Negative Cash Flow Breakdown
Net loss attributable to common ...
Accounts payable and other curre...
Stock based compensation
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-
-
-2,018,245
-3,248,958
Net loss attributable to common stockholders
-1,547,912
-5,389,611
-
-
Depreciation and amortization
72,860
79,547
81,603
79,866
Stock-based compensation
-
206,105
-
-
Non-cash lease expense
-
294,026
-
-
Stock based compensation
-167,326
-
72,442
144,884
Warrant inducement expense
-
0
-
-
Amortization of right-of-use operating lease asset
-143,638
-
73,913
145,350
Prepaid expenses and other current assets
-79,879
274,500
-344,593
82,574
Accounts payable and other current liabilities
-626,991
362,450
-418,055
-190,287
Due to related parties
0
-169,596
-10,608
-124,144
Net cash used in operating activities
-1,896,539
-1,750,381
-1,874,357
-1,658,717
Purchases of property and equipment
9,150
2,051
1,653
-
Cash used in investing activities
-9,150
-2,051
-1,653
-
Proceeds from the issuance of common stock
1,904,211
-848,477
4,005,476
3,744,466
Payments for offering costs related to equity issuance exercises
82,568
66,252
1,021,602
-
Proceeds from exercise of warrants standard terms
-
0
-
-
Proceeds from exercise of warrants induced terms
-
848,537
-
-
Commission paid related to warrant inducement
-
0
-
-
Legal fees paid related to warrant inducement
-
0
-
-
Proceeds from the issuance of common stock upon class a and class b warrant exercises
-
-
-
0
Payments for deferred offering costs related to future equity issuance
-
129,329
-
-
Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units and net stock option expense
4,488
975
1,239
3,344
Net cash provided (used in) by financing activities
1,817,155
-196,496
2,982,635
3,741,122
Effect of exchange rate on changes on cash
-4,123
19,208
-3,460
6,252
Net decrease in cash, cash equivalents and restricted cash
-92,657
-1,929,720
1,103,165
2,088,657
Cash, cash equivalents and restricted cash at beginning of period
5,125,386
5,951,941
5,951,941
5,599,074
Cash, cash equivalents and restricted cash
5,032,729
5,125,386
7,055,106
5,951,941
Par value of shares issued for vested restricted stock units and net stock option exercise
0.03
-
-
-
Deferred offering costs not yet paid
214,015
-
-
-
Cash and cash equivalents
4,933,579
-
-
-
Restricted cash
99,150
-
-
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from the
issuance of common stock
$1,904,211
Net cash provided
(used in) by financing...
$1,817,155
(34021.13%↑ Y/Y)
Canceled cashflow
$87,056
Net decrease in
cash, cash...
-$92,657
(94.66%↑ Y/Y)
Canceled cashflow
$1,817,155
something is missing
$436,589
Prepaid expenses and
other current assets
-$79,879
(51.30%↑ Y/Y)
Depreciation and
amortization
$72,860
(-11.83%↓ Y/Y)
Payments for offering
costs related to...
$82,568
Tax withholding
payments or tax...
$4,488
(-16.22%↓ Y/Y)
Net cash used in
operating activities
-$1,896,539
(-10.59%↓ Y/Y)
Canceled cashflow
$589,328
Cash used in
investing activities
-$9,150
Effect of exchange rate
on changes on cash
-$4,123
(73.39%↑ Y/Y)
Net loss
attributable to common...
-$1,547,912
(12.14%↑ Y/Y)
Accounts payable and
other current...
-$626,991
(-356.02%↓ Y/Y)
Stock based
compensation
-$167,326
(-330.98%↓ Y/Y)
Amortization of right-of-use
operating lease asset
-$143,638
Purchases of property and
equipment
$9,150
Buy us a coffee
AETHLON MEDICAL INC (AEMD)
AETHLON MEDICAL INC (AEMD)